We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Vaccine Designed to Shield AIDS Carriers

By Labmedica staff writers
Posted on 09 Feb 2007
A two-stage vaccine against HIV that is designed to benefit individuals already carrying the virus has demonstrated nearly complete protection against developing clinical AIDS in early stage trials with non-human primates.

The vaccine, which was developed by Geovax Incorporated (Atlanta, GA, USA), comprises a combination of DNA and modified vaccinia Ankara (MVA) to stimulate production of anti-HIV antibodies and anti-HIV T cells. More...
MVA virus, which has been engineered to express foreign genes, is widely considered as the vaccinia virus strain of choice for clinical investigation because of its high safety profile.

In preclinical trials the DNA/MVA vaccine was 96% effective in protecting non-human primates against developing clinical AIDS. Twenty-two out of 23 non-human primates that received the vaccine were protected against developing clinical signs of AIDS. The animal that was not protected received only a partial dose of vaccine. Over 83% of the unvaccinated controls (5/6) died of clinical AIDS within eight months after receiving live HIV, and all the animals had levels of virus in the blood stream 10 to 100-fold higher than in typical HIV-1 infected humans.



Related Links:
Geovax Incorporated

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Clinical Informatics Platform
CLARION™
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The findings suggest that people with mpox can transmit the virus even without clinical symptoms (image credit: Adobe Stock)

Study Finds Hidden Mpox Infections May Drive Ongoing Spread

Mpox continues to circulate despite vaccination, and many cases show no known link to a symptomatic partner. The role of people without symptoms has remained uncertain, limiting clarity on how transmission persists.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.